Niklas Czeloth

2.2k total citations · 1 hit paper
20 papers, 1.8k citations indexed

About

Niklas Czeloth is a scholar working on Immunology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Niklas Czeloth has authored 20 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 4 papers in Molecular Biology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Niklas Czeloth's work include T-cell and B-cell Immunology (12 papers), Immunotherapy and Immune Responses (9 papers) and Immune Cell Function and Interaction (9 papers). Niklas Czeloth is often cited by papers focused on T-cell and B-cell Immunology (12 papers), Immunotherapy and Immune Responses (9 papers) and Immune Cell Function and Interaction (9 papers). Niklas Czeloth collaborates with scholars based in Germany, United States and France. Niklas Czeloth's co-authors include Reinhold Förster, Jörg Zwirner, Ziba Kiafard, Mariette Mohaupt, Thomas Blankenstein, Golo Henning, Lars Ohl, Gabriele Hintzen, Günter Bernhardt and Oliver Pabst and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Niklas Czeloth

20 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CCR7 Governs Skin Dendritic Cell Migration under Inflammatory and Steady-State Conditions

2004 804 citations Lars Ohl, Mariette Mohaupt et al. Immunity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Niklas Czeloth Germany	17	1.4k	428	371	114	112	20	1.8k
Satoko Tahara‐Hanaoka Japan	23	1.5k 1.1×	355 0.8×	297 0.8×	81 0.7×	166 1.5×	51	1.9k
Naoko Aoki Japan	28	1.2k 0.8×	569 1.3×	510 1.4×	82 0.7×	71 0.6×	70	1.8k
Kerstin Siegmund Austria	17	1.5k 1.1×	380 0.9×	280 0.8×	59 0.5×	132 1.2×	35	1.9k
Nobuaki Kawamura Japan	19	1.2k 0.8×	293 0.7×	363 1.0×	122 1.1×	101 0.9×	51	1.9k
Leonie M. van Duivenvoorde Netherlands	22	1.9k 1.4×	599 1.4×	386 1.0×	242 2.1×	95 0.8×	46	2.5k
Jean‐Michel Bridon France	9	1.6k 1.1×	469 1.1×	385 1.0×	45 0.4×	166 1.5×	10	2.0k
Hua-Chen Chang United States	17	1.2k 0.9×	393 0.9×	311 0.8×	65 0.6×	108 1.0×	18	1.6k
Belinda Palermo Italy	20	1.4k 1.0×	705 1.6×	304 0.8×	47 0.4×	90 0.8×	42	1.9k
Irina Apostolou United States	18	3.0k 2.1×	503 1.2×	459 1.2×	116 1.0×	110 1.0×	24	3.5k
Danielle L. Drayton United States	7	1.2k 0.9×	383 0.9×	195 0.5×	43 0.4×	89 0.8×	7	1.6k

Countries citing papers authored by Niklas Czeloth

Since Specialization

Citations

This map shows the geographic impact of Niklas Czeloth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niklas Czeloth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niklas Czeloth more than expected).

Fields of papers citing papers by Niklas Czeloth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niklas Czeloth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niklas Czeloth. The network helps show where Niklas Czeloth may publish in the future.

Co-authorship network of co-authors of Niklas Czeloth

This figure shows the co-authorship network connecting the top 25 collaborators of Niklas Czeloth. A scholar is included among the top collaborators of Niklas Czeloth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niklas Czeloth. Niklas Czeloth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Menter, Alan, Petr Arenberger, Sigrid Balser, et al.. (2020). Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert Opinion on Biological Therapy. 21(1). 87–96. 18 indexed citations

Cohen, Stanley, et al.. (2019). Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). Expert Opinion on Biological Therapy. 19(10). 1097–1105. 21 indexed citations

Wynne, Christopher, et al.. (2017). A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opinion on Investigational Drugs. 26(8). 889–896. 23 indexed citations

Wynne, Christopher, Ivo Sonderegger, Lien Gheyle, et al.. (2016). Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects. Expert Opinion on Investigational Drugs. 25(12). 1361–1370. 50 indexed citations

Grabski, Elena, Frank Klawonn, Marius Döring, et al.. (2015). Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64+ cells. Scientific Reports. 5(1). 18308–18308. 4 indexed citations

König, Martin, Benjamin Dälken, André Engling, et al.. (2014). A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunology and Cell Biology. 93(4). 396–405. 29 indexed citations

Mayer, Christian T., Julia M. Huntenburg, Amrita Nandan, et al.. (2013). CD4 blockade directly inhibits mouse and human CD4+ T cell functions independent of Foxp3+ Tregs. Journal of Autoimmunity. 47. 73–82. 11 indexed citations

Heffner, Leonard T., Sundar Jagannath, Todd M. Zimmerman, et al.. (2012). BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity. Blood. 120(21). 4042–4042. 50 indexed citations

Seth, Sebastian, Simon Danisch, Michael K. Maier, et al.. (2011). Intranodal Interaction with Dendritic Cells Dynamically Regulates Surface Expression of the Co-stimulatory Receptor CD226 Protein on Murine T Cells. Journal of Biological Chemistry. 286(45). 39153–39163. 19 indexed citations

10.

Rathinasamy, Anchana, Niklas Czeloth, Oliver Pabst, Reinhold Förster, & Günter Bernhardt. (2010). The Origin and Maturity of Dendritic Cells Determine the Pattern of Sphingosine 1-Phosphate Receptors Expressed and Required for Efficient Migration. The Journal of Immunology. 185(7). 4072–4081. 57 indexed citations

11.

Trollmo, Christina, Christian Becker, Helmut Jonuleit, et al.. (2010). (1125) - Selective Activation of Naturally Occurring Regulatory T Cells (Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers of Clinical Activity and Early Phase II Results in Patients with Rheumatoid Arthritis (RA). 4 indexed citations

12.

Quast, Thomas, Niklas Czeloth, Reinhold Förster, et al.. (2009). Cytohesin-1 controls the activation of RhoA and modulates integrin-dependent adhesion and migration of dendritic cells. Blood. 113(23). 5801–5810. 51 indexed citations

13.

Koenecke, Christian, Niklas Czeloth, Anja Bubke, et al.. (2009). Alloantigen‐specific de novo‐induced Foxp3⁺ Treg revert in vivo and do not protect from experimental GVHD. European Journal of Immunology. 39(11). 3091–3096. 113 indexed citations

14.

Seth, Sebastian, Anna‐Maria Georgoudaki, Benedict J. Chambers, et al.. (2009). Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells. Journal of Leukocyte Biology. 86(1). 91–101. 38 indexed citations

15.

Czeloth, Niklas, Angela Schippers, Norbert Wagner, et al.. (2007). Sphingosine-1 Phosphate Signaling Regulates Positioning of Dendritic Cells within the Spleen. The Journal of Immunology. 179(9). 5855–5863. 50 indexed citations

16.

Maier, Michael K., Sebastian Seth, Niklas Czeloth, et al.. (2007). The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. European Journal of Immunology. 37(8). 2214–2225. 58 indexed citations

17.

Wendland, Meike, Niklas Czeloth, Nicolas Mach, et al.. (2007). CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proceedings of the National Academy of Sciences. 104(15). 6347–6352. 195 indexed citations

18.

Pabst, Oliver, Thorsten Peters, Niklas Czeloth, et al.. (2005). Cutting Edge: Egress of Newly Generated Plasma Cells from Peripheral Lymph Nodes Depends on β2 Integrin. The Journal of Immunology. 174(12). 7492–7495. 34 indexed citations

19.

Czeloth, Niklas, Günter Bernhardt, Fred Hofmann, Harald Genth, & Reinhold Förster. (2005). Sphingosine-1-Phosphate Mediates Migration of Mature Dendritic Cells. The Journal of Immunology. 175(5). 2960–2967. 166 indexed citations

20.

Ohl, Lars, Mariette Mohaupt, Niklas Czeloth, et al.. (2004). CCR7 Governs Skin Dendritic Cell Migration under Inflammatory and Steady-State Conditions. Immunity. 21(2). 279–288. 804 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact